Antibody Structure

What an antibody is, in one picture

Picture a capital letter Y. The two arms reach out to grab a target; the single stem points back toward home base. That is the whole logic of an antibody — also called an immunoglobulin (Ig). Each arm ends in a binding site shaped to clamp onto one specific molecular feature, called an epitope, on a virus, bacterium, toxin, or any foreign molecule the immune system has flagged. The stem does something completely different: it never touches the target. Instead it sticks out as a handle that other parts of the immune system — complement proteins, phagocytes, natural killer cells — grab onto to finish the job.

This split is the single most important thing to understand about antibody architecture: the molecule is modular. The variable tips answer the question what do we attack? and the constant stem answers what do we do about it? A B cell can keep the same tips and swap the stem (class switching) to change the response from, say, a circulating IgG to a mucosal IgA — same target, different weapon. That modularity is why a few hundred genes can defend against essentially any molecule nature or chemistry can throw at the body.

How the four chains build the Y

An antibody monomer is four polypeptide chains: two identical heavy chains (about 50 kDa, ~440–450 residues each in IgG) and two identical light chains (about 25 kDa, ~220 residues each). They fold into a series of compact, sandwich-shaped immunoglobulin domains — the canonical Ig fold, two stacked beta-sheets pinned by an internal disulfide bond, about 110 amino acids each. A light chain has two such domains: one variable (V_L) and one constant (C_L). A heavy chain in IgG has four: V_H, C_H1, C_H2, and C_H3.

The chains snap together by domain pairing and disulfide bonds. Each light chain lies alongside the V_H–C_H1 half of one heavy chain, and the two heavy chains zip together along their C_H2–C_H3 region. The result is two outer arms (V_L+C_L paired with V_H+C_H1 — these are the Fab fragments) and one central stem (the paired C_H2+C_H3 — the Fc fragment). Between them sits a flexible, proline-rich hinge region, stabilized by interchain disulfide bonds, that lets the two arms splay and flex independently so a single antibody can reach two epitopes spaced apart on a surface.

At the very tips of the two V domains sit three short, ultra-variable loops each — the complementarity-determining regions (CDR1, CDR2, CDR3). The six CDRs from the paired V_H and V_L cluster into a single surface called the paratope, the actual gripping hand. The rest of the variable domain — the framework — is a conserved scaffold that holds those loops in position. CDR-H3, which straddles the V-D-J junction, is the most variable and usually contributes the most binding energy.

Fab arms vs Fc stem: two jobs, two halves

The names Fab and Fc are historical: when Rodney Porter digested IgG with the protease papain in 1959, it cut cleanly above the hinge into two identical antigen-binding fragments (Fab) and one fragment that crystallized readily (Fc). That experiment, and Gerald Edelman's parallel work reducing the disulfide bonds to separate the heavy and light chains, is how the four-chain model was proven — and won them the 1972 Nobel Prize in Physiology or Medicine.

Property	Fab arm (the tips)	Fc region (the stem)
Domains	VL, CL, VH, CH1	CH2, CH3 (paired, ×2)
Sequence variability	High — variable + CDR loops	Constant within an isotype
Function	Binds one specific epitope	Recruits effector mechanisms
Number per monomer	2 (so IgG is bivalent)	1
Key partners	Antigen / epitope	C1q, Fcγ/Fcε receptors, FcRn
Determines	What gets targeted	What response is triggered
Swappable?	Tuned by hypermutation	Swapped by class switching
Glycosylation	Usually none (variable region)	N-linked glycan at Asn297 — tunes effector strength

The Fc region is far from inert. A single N-linked glycan attached at asparagine 297 in each C_H2 domain controls how strongly the Fc engages its receptors: removing the terminal fucose from that glycan can boost antibody-dependent cellular cytotoxicity (ADCC) by 10- to 100-fold, a property deliberately engineered into anticancer antibodies like obinutuzumab. The Fc is also what the neonatal Fc receptor (FcRn) recycles inside cells, rescuing IgG from lysosomal degradation and giving it a serum half-life of about 21 days — the longest of any serum protein and the reason therapeutic antibodies can be dosed only every few weeks.

Where the diversity comes from

The central paradox of immunology: the human genome carries roughly 20,000 protein-coding genes, but the adaptive immune system can produce well over 10¹² distinct antibodies. The body does not store a gene for each one. Instead it assembles them combinatorially during B-cell development in the bone marrow.

The heavy-chain variable region is stitched together by V(D)J recombination: the cell randomly picks one of ~40 functional V (variable) segments, ~25 D (diversity) segments, and 6 J (joining) segments and splices them into a contiguous exon, deleting the DNA in between. The light chain joins only V and J segments. The recombinase enzymes RAG1 and RAG2 make the cuts at recombination signal sequences, and the joining is deliberately sloppy: the enzyme terminal deoxynucleotidyl transferase (TdT) sprinkles random, non-templated nucleotides into the junctions. That junctional diversity is concentrated in CDR-H3 and is the single largest source of variety.

Multiply it out: roughly 40 × 25 × 6 heavy-chain combinations, times the light-chain combinations, times random pairing of any heavy with any light, gives on the order of 10⁶–10⁷ distinct receptors before a single antigen is even seen. Junctional diversity adds several more orders of magnitude. Then, once a B cell encounters its antigen in a germinal center, somatic hypermutation — driven by the enzyme AID (activation-induced cytidine deaminase) at a blistering ~10^-3 mutations per base per division, a million times the background rate — peppers the variable region with point mutations. Cells whose mutated receptors bind tighter are selected to survive (affinity maturation), and the rest die. This is Darwinian selection running inside your lymph nodes over a few days.

The five isotypes

All antibodies from one B-cell clone share the same variable tips, but the constant heavy chain comes in five flavors — the isotypes — each routing a different effector strategy. Class switching lets a B cell change isotype while keeping its antigen specificity.

Isotype	Heavy chain	Form	Serum level	Main role
IgG	gamma (γ)	Monomer	~10 mg/mL (~75%)	Secondary response, complement, crosses placenta
IgM	mu (µ)	Pentamer (10 sites)	~1.5 mg/mL	First responder, strongest complement activator
IgA	alpha (α)	Monomer / dimer	~2 mg/mL serum	Mucosal defense, saliva, breast milk
IgE	epsilon (ε)	Monomer	~0.0003 mg/mL	Allergy, mast-cell arming, antiparasite
IgD	delta (δ)	Monomer	~0.04 mg/mL	Naive B-cell surface receptor; signaling

Note the valency trick. A single IgG has two arms (bivalent); secreted IgM is a pentamer linked by a J chain, giving it ten binding sites. Even when each individual arm binds weakly, ten arms latching onto a repetitive viral or bacterial surface produce an enormous combined avidity — which is how early, low-affinity IgM still clears pathogens effectively before affinity maturation has had time to refine IgG.

The numbers that matter

• Size. An IgG is about 150 kDa, roughly 10 nm across the Y. IgM pentamer is about 970 kDa. Each Ig domain is ~110 amino acids folded into a ~4 × 2.5 nm beta-sandwich.
• Affinity. Naive antibodies bind around K_d ≈ 10^-6 M (micromolar). After affinity maturation, K_d drops to 10^-9–10^-12 M (nanomolar to picomolar) — a 1,000- to 1,000,000-fold tighter grip, near the ceiling for a protein-protein interaction.
• Diversity. >10¹² distinct specificities from ~40 V, ~25 D, 6 J heavy-chain segments plus light-chain segments, junctional diversity, and somatic hypermutation.
• Half-life. IgG persists ~21 days in serum thanks to FcRn recycling; IgE lasts only ~2 days in circulation (but weeks bound to mast cells).
• Hypermutation rate. AID drives ~10^-3 mutations per base per cell division in the variable region — about a million times the genomic background.
• Output. A single mature plasma cell secretes on the order of 1,000–2,000 antibody molecules per second. Total serum immunoglobulin in an adult is roughly 12–15 g/L.
• Bonds. A typical IgG has about 12 intrachain disulfide bonds (one per domain) plus 4 interchain bonds (hinge and light-heavy), holding the four chains rigidly together.

Where antibody structure shows up

• Vaccines. Every vaccine works by teaching B cells to make antibodies whose Fab arms grip a pathogen, then mature for higher affinity. mRNA COVID-19 vaccines encode the SARS-CoV-2 spike so the body raises neutralizing IgG against it.
• Therapeutic monoclonal antibodies. Drugs ending in -mab are engineered antibodies: trastuzumab (Herceptin) grips HER2 on breast-cancer cells; adalimumab (Humira) grips TNF-α in autoimmune disease; pembrolizumab blocks the PD-1 checkpoint. Most are IgG1, chosen for its strong Fc effector functions and long half-life. The global market exceeds $200 billion a year.
• Diagnostics. ELISA, lateral-flow rapid tests (pregnancy, COVID), and Western blots all exploit the Fab's exquisite specificity to detect a single target molecule in a complex sample.
• Allergy and anaphylaxis. IgE bound by its Fc to mast cells cross-links when its Fab arms catch allergen, triggering histamine release. The drug omalizumab is an anti-IgE antibody that mops up free IgE.
• Autoimmune disease. When the variable region mistakenly matures against self, you get autoantibodies — anti-dsDNA in lupus, anti-acetylcholine-receptor in myasthenia gravis, rheumatoid factor (an antibody against the Fc of other IgGs) in rheumatoid arthritis.
• Passive immunity. IgG crosses the placenta via FcRn, and IgA passes in breast milk, giving newborns ready-made maternal antibodies for their first months before their own repertoire develops.

Common misconceptions

• "Antibodies kill the pathogen directly." Mostly no. A bare antibody usually just tags, clumps (agglutinates), or neutralizes a target. The actual killing is done by what the Fc recruits — complement, phagocytes, NK cells. The major exception is neutralizing antibodies that physically block a virus from entering a cell.
• "The whole molecule is variable." Only the V domains — and within them, mostly the six CDR loops — vary. The constant domains (C_L, C_H1–3) are nearly identical across all antibodies of a given isotype. That is precisely what lets the immune system standardize effector machinery.
• "Each antibody binds one antigen molecule." An IgG has two identical arms and binds two epitopes; IgM has ten. Bivalency and multivalency dramatically raise functional avidity over the affinity of a single arm.
• "Higher affinity is always better." Not for early defense. Low-affinity, high-avidity IgM is essential before affinity maturation finishes; and excessively tight binding can slow an antibody's ability to scan and dissociate from decoys.
• "Fc is just a structural anchor." The Fc actively shapes the response: its glycan at Asn297 tunes ADCC and complement strength, FcRn governs half-life, and different isotype Fc regions engage different receptor sets. Antibody engineers spend enormous effort on the Fc, not just the binding site.
• "Antibodies and B-cell receptors are different molecules." A membrane-bound B-cell receptor is essentially the same immunoglobulin with a transmembrane tail; secreted antibody is the same protein with the membrane anchor spliced out. Same Fab, different C-terminus.